Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News IMV Inc IMVIF

Healthcare Biotechnology
IMV Inc. is a Canada-based company. The Company has no business operations.

Recent & Breaking News (GREY:IMVIF)

IMV Inc. Launches Plans to Advance Clinical Development of a Vaccine Candidate Against COVID-19

Business Wire March 18, 2020

IMV Inc. Announces Breakthrough Data from DeCidE1, its Ongoing Phase 2 Study of DPX-Survivac in Patients with Advanced Recurrent Ovarian Cancer

Business Wire February 25, 2020

5 Promising Stocks under $5

Jonathon Brown February 24, 2020

IMV to Host Conference Call & Webcast to Report Updated Results from DeCidE1, its Ongoing Phase 2 Study of DPX-Survivac in Patients with Advanced Recurrent Ovarian Cancer

Business Wire February 20, 2020

IMV Announces Board Retirement

Business Wire February 14, 2020

Clinical Translational Data Supporting DPX-Survivac Mechanism of Action to be Presented at 2020 ASCO-SITC Clinical Immuno-Oncology Symposium

Business Wire February 4, 2020

IMV to Present at 2020 BIO CEO & Investor Conference

Business Wire January 31, 2020

IMV to Host Key Opinion Leader Symposium on Role of Survivin in Cancer Biology and Potential of DPX-Survivac

Business Wire January 24, 2020

IMV to Participate at Two Upcoming Investor Conferences

Business Wire November 27, 2019

IMV Inc. Announces Third Quarter 2019 Financial Results and Provides Corporate Update

Business Wire November 8, 2019

Navidea Biopharmaceuticals Announces Preclinical Therapeutic Research Collaboration with IMV Inc. to Explore the Potential Combinatory Effect with Their Platform-Based Immunotherapies

Business Wire November 7, 2019

Updated Results from Phase 2 SPiReL Study Evaluating IMV's DPX-Survivac as Combination Therapy in Patients with r/r DLBCL to be Presented at 61st American Society of Hematology (ASH) Annual Meeting

Business Wire November 6, 2019

IMV to Present Clinical Translational Data from DeCidE1 Study of DPX-Survivac at SITC 2019 Annual Meeting

Business Wire November 5, 2019

IMV Appoints Joanne Schindler, M.D., D.V.M. as Chief Medical Officer

Business Wire October 30, 2019

IMV Inc. to Announce Third Quarter 2019 Results and Host a Conference Call and Webcast on November 8, 2019

Business Wire October 29, 2019

/ C O R R E C T I O N From Source - IMV Inc /

Business Wire October 16, 2019

IMV Inc. to Present at Upcoming Investor Conference

Business Wire October 11, 2019

Preliminary Results From IMV's Phase 2 Basket Trial Evaluating DPX-Survivac as a Combination Therapy in Patients With Advanced and Metastatic Solid Tumors to Be Presented at ESMO Congress 2019

Business Wire September 30, 2019

Preliminary Results From IMV's Phase 2 Basket Trial Evaluating DPX-Survivac as a Combination Therapy in Patients with Advanced and Metastatic Solid Tumors to Be Presented at ESMO Congress 2019

Business Wire September 23, 2019

IMV Announces Research Collaboration with The Wistar Institute to Develop New Targeted Immunotherapy Against the Common BRAF Cancer Mutation

Business Wire September 4, 2019